138 related articles for article (PubMed ID: 1713821)
1. Evaluation of thiophosphoric acid alkaloid derivatives from Chelidonium majus L. ("Ukrain") as an immunostimulant in patients with various carcinomas.
Nowicky JW; Staniszewski A; Zbroja-Sontag W; Slesak B; Nowicky W; Hiesmayr W
Drugs Exp Clin Res; 1991; 17(2):139-43. PubMed ID: 1713821
[TBL] [Abstract][Full Text] [Related]
2. Lymphocyte subsets in patients with lung cancer treated with thiophosphoric acid alkaloid derivatives from Chelidonium majus L. (Ukrain).
Staniszewski A; Slesak B; Kołodziej J; Harłozińska-Szmyrka A; Nowicky JW
Drugs Exp Clin Res; 1992; 18 Suppl():63-7. PubMed ID: 1305047
[TBL] [Abstract][Full Text] [Related]
3. Ukrain, an alkaloid thiophosphoric acid derivative of Chelidonium majus L. protects human fibroblasts but not human tumour cells in vitro against ionizing radiation.
Cordes N; Plasswilm L; Bamberg M; Rodemann HP
Int J Radiat Biol; 2002 Jan; 78(1):17-27. PubMed ID: 11747550
[TBL] [Abstract][Full Text] [Related]
4. Ukrain both as an anti cancer and immunoregulatory agent.
Nowicky JW; Manolakis G; Meijer D; Vatanasapt V; Brzosko WJ
Drugs Exp Clin Res; 1992; 18 Suppl():51-4. PubMed ID: 1305045
[TBL] [Abstract][Full Text] [Related]
5. In vitro effects of Chelidonium majus L. alkaloid thiophosphoric acid conjugates (Ukrain) on the phenotype of normal human lymphocytes.
Slesak B; Nowicky JW; Harłozinska A
Drugs Exp Clin Res; 1992; 18 Suppl():17-21. PubMed ID: 1305038
[TBL] [Abstract][Full Text] [Related]
6. Ukrain (NSC-631570) in experimental and clinical studies: a review.
Jagiello-Wójtowicz E; Kleinrok Z; Urbanska EM
Drugs Exp Clin Res; 1998; 24(5-6):213-9. PubMed ID: 10190077
[TBL] [Abstract][Full Text] [Related]
7. Potential therapeutic efficacy of Ukrain (NSC 631570) in AIDS patients with Kaposi's sarcoma.
Voltchek IV; Liepins A; Nowicky JW; Brzosko WJ
Drugs Exp Clin Res; 1996; 22(3-5):283-6. PubMed ID: 8899349
[TBL] [Abstract][Full Text] [Related]
8. The effects of thiophosphoric acid (Ukrain) on cervical cancer, stage IB bulky.
Pengsaa P; Wongpratoom W; Vatanasapt V; Udomthavornsuk B; Mairieng E; Tangvorapongchai V; Pesi M; Krusan S; Boonvisoot V; Nowicky JW
Drugs Exp Clin Res; 1992; 18 Suppl():69-72. PubMed ID: 1305048
[TBL] [Abstract][Full Text] [Related]
9. Proapoptotic activity of Ukrain is based on Chelidonium majus L. alkaloids and mediated via a mitochondrial death pathway.
Habermehl D; Kammerer B; Handrick R; Eldh T; Gruber C; Cordes N; Daniel PT; Plasswilm L; Bamberg M; Belka C; Jendrossek V
BMC Cancer; 2006 Jan; 6():14. PubMed ID: 16417634
[TBL] [Abstract][Full Text] [Related]
10. Modulation of immune effector cell cytolytic activity and tumour growth inhibition in vivo by Ukrain (NSC 631570).
Liepins A; Nowicky JW
Drugs Exp Clin Res; 1996; 22(3-5):103-13. PubMed ID: 8899312
[TBL] [Abstract][Full Text] [Related]
11. Results of Ukrain monotherapy of prostate cancer.
Uglyanitsa KN; Nechiporenko NA; Nefyodov LI; Doroshenko YM; Brzosko W; Nowicky W
Drugs Exp Clin Res; 2000; 26(5-6):191-3. PubMed ID: 11345026
[TBL] [Abstract][Full Text] [Related]
12. In-vitro toxicity of Ukrain against human Ewing tumor cell lines.
Lanvers-Kaminsky C; Nolting DM; Köster J; Schröder A; Sandkötter J; Boos J
Anticancer Drugs; 2006 Oct; 17(9):1025-30. PubMed ID: 17001175
[TBL] [Abstract][Full Text] [Related]
13. Chelidonium majus L. (Ukrain) in the treatment of cancer patients.
Lohninger A; Hamler F
Drugs Exp Clin Res; 1992; 18 Suppl():73-7. PubMed ID: 1305049
[TBL] [Abstract][Full Text] [Related]
14. Basic central pharmacological properties of thiophosphoric acid alkaloid derivatives from Chelidonium majus L.
Kleinrok Z; Jagiełło-Wójtowicz E; Matuszek B; Chodkowska A
Pol J Pharmacol Pharm; 1992; 44(3):227-39. PubMed ID: 1470561
[TBL] [Abstract][Full Text] [Related]
15. Ukrain therapy in a frontal anaplastic grade III astrocytoma (case report).
Steinacker J; Kroiss T; Korsh OB; Melnyk A
Drugs Exp Clin Res; 1996; 22(3-5):275-7. PubMed ID: 8899347
[TBL] [Abstract][Full Text] [Related]
16. Influence of Ukrain on patients with surgically treated breast cancer. Part III. The immune system.
Fomin KA; Uglyanica KN; Nefyodov LI; Djurd TI; Nowicky JW; Brzosko WJ; Jankowski A
Drugs Exp Clin Res; 1996; 22(3-5):143-5. PubMed ID: 8899318
[TBL] [Abstract][Full Text] [Related]
17. Comparative evaluation of the efficiency of various Ukrain doses in the combined treatment of breast cancer. Report 1. Clinical aspects of Ukrain application.
Uglyanitsa KN; Nefyodov LI; Brzosko V
Drugs Exp Clin Res; 2000; 26(5-6):223-30. PubMed ID: 11345029
[TBL] [Abstract][Full Text] [Related]
18. Clinical studies of Ukrain in terminal cancer patients (phase II).
Musianowycz J; Judmajer F; Manfreda D; Spängler P; Albrecht H; Hoffmann J; Meijer D
Drugs Exp Clin Res; 1992; 18 Suppl():45-50. PubMed ID: 1305043
[TBL] [Abstract][Full Text] [Related]
19. Teratological evaluation of Ukrain in hamsters and rats.
Juszkiewicz T; Minta M; Wlodarczyk B; Biernacki B
Drugs Exp Clin Res; 1992; 18 Suppl():23-9. PubMed ID: 1305039
[TBL] [Abstract][Full Text] [Related]
20. Effect of six-month treatment with Ukrain on early osteoporosis induced by ovariectomy in rats. Part I: Preliminary studies of bone parameters.
Jagiełło-Wojtowicz E; Kleinrok Z; Nowicky JW; Jabłonski M; Gorzelak M; Chodkowska A; Feldo M; Matuszek B
Drugs Exp Clin Res; 1996; 22(3-5):173-6. PubMed ID: 8899324
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
